Advertisement

Clinical and Experimental Medicine

, Volume 17, Issue 3, pp 415–416 | Cite as

Vismodegib and risk of cholestatic injury: should we screen candidate patients?

  • Michelangelo Vestita
  • Lucia Lospalluti
  • Giuseppe Giudice
  • Domenico Bonamonte
  • Ignazio Rossiello
  • Angela Filoni
Letter to the Editor

Keywords

Metformin Losartan Cholestasis Basal Cell Carcinoma Cholelithiasis 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Notes

Compliance with ethical standards

Conflict of interest

None.

Supplementary material

10238_2016_433_MOESM1_ESM.jpg (254 kb)
Supplemental Fig. 1. MRI T2 weighted-spin echo-axial view shows minute hypo-intense filling defects in the choledochus lumen (JPEG 254 kb)
10238_2016_433_MOESM2_ESM.jpg (251 kb)
Supplemental Fig. 2. MRI T2 weighted-spin echo-axial view shows minute hypo-intense filling defects in the cystic duct lumen (JPEG 251 kb)
10238_2016_433_MOESM3_ESM.jpg (251 kb)
Supplemental Fig. 3. MRI T2 weighted-spin echo-coronal view shows minute hypointense filling defects in the cystic duct lumen (JPEG 251 kb)

References

  1. 1.
    Ash MM, Jolly PS. Cholestatic hepatic injury associated with vismodegib, aspirin, and naproxen use: a case study and review of vismodegib safety. Int J Dermatol. 2015;54:370–4.CrossRefPubMedGoogle Scholar
  2. 2.
    Sekulic A, Migden MR, Oro AE, et al. Efficacy and safety of vismodegib in advanced basal-cell carcinoma. N Engl J Med. 2012;366:2171–9.CrossRefPubMedPubMedCentralGoogle Scholar
  3. 3.
    LoRusso PM, Piha-Paul SA, Mita M, et al. Co-administration of vismodegib with rosiglitazone or combined oral contraceptive in patients with locally advanced or metastatic solid tumors: a pharmacokinetic assessment of drug–drug interaction potential. Cancer Chemother Pharmacol. 2013;71:193–202.CrossRefPubMedGoogle Scholar
  4. 4.
    LoRusso PM, Rudin CM, Reddy JC, et al. Phase I trial of hedgehog pathway inhibitor vismodegib (GDC-0449) in patients with refractory, locally advanced or metastatic solid tumors. Clin Cancer Res. 2011;17:2502–11.CrossRefPubMedPubMedCentralGoogle Scholar
  5. 5.
    Ventarola DJ, Silverstein DI. Vismodegib-associated hepatotoxicity: a potential side effect detected in postmarketing surveillance. J Am Acad Dermatol. 2014;71:397–8.CrossRefPubMedGoogle Scholar

Copyright information

© Springer International Publishing Switzerland 2016

Authors and Affiliations

  • Michelangelo Vestita
    • 1
  • Lucia Lospalluti
    • 2
  • Giuseppe Giudice
    • 1
  • Domenico Bonamonte
    • 2
  • Ignazio Rossiello
    • 3
  • Angela Filoni
    • 2
  1. 1.Section of Plastic and Reconstructive Surgery, Department of Emergency and Organ TransplantationUniversity of BariBariItaly
  2. 2.Section of Dermatology, Department of Biomedical Science and Human OncologyUniversity of BariBariItaly
  3. 3.Section of Diagnostic Imaging, Department of Interdisciplinary MedicineUniversity of BariBariItaly

Personalised recommendations